Beta Bionics (NASDAQ:BBNX – Get Free Report) and Hyperfine (NASDAQ:HYPR – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, profitability, valuation, analyst recommendations, institutional ownership, earnings and risk.
Analyst Recommendations
This is a breakdown of current recommendations for Beta Bionics and Hyperfine, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Beta Bionics | 1 | 4 | 7 | 0 | 2.50 |
| Hyperfine | 1 | 1 | 3 | 0 | 2.40 |
Beta Bionics currently has a consensus price target of $21.90, suggesting a potential upside of 1.01%. Hyperfine has a consensus price target of $2.03, suggesting a potential upside of 162.37%. Given Hyperfine’s higher probable upside, analysts plainly believe Hyperfine is more favorable than Beta Bionics.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Beta Bionics | -61.31% | -26.30% | -23.25% |
| Hyperfine | -210.75% | -97.88% | -61.81% |
Earnings & Valuation
This table compares Beta Bionics and Hyperfine”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Beta Bionics | $100.25 million | 9.73 | -$73.20 million | ($1.65) | -13.14 |
| Hyperfine | $11.40 million | 7.21 | -$35.57 million | ($0.38) | -2.04 |
Hyperfine has lower revenue, but higher earnings than Beta Bionics. Beta Bionics is trading at a lower price-to-earnings ratio than Hyperfine, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
15.0% of Hyperfine shares are owned by institutional investors. 5.3% of Beta Bionics shares are owned by company insiders. Comparatively, 26.3% of Hyperfine shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Risk and Volatility
Beta Bionics has a beta of 3.37, indicating that its share price is 237% more volatile than the S&P 500. Comparatively, Hyperfine has a beta of 1.41, indicating that its share price is 41% more volatile than the S&P 500.
Summary
Beta Bionics beats Hyperfine on 8 of the 14 factors compared between the two stocks.
About Beta Bionics
Beta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.
About Hyperfine
Hyperfine, Inc., a medical device company, provides magnetic resonance imaging (MRI) products in the United States. The company offers Swoop Portable MR imaging system, which offers portable brain neuroimaging; and support and technical assistance services. It serves ICU, comprehensive, and primary stroke accredited facilities through direct sales and distributors. Hyperfine, Inc. was founded in 2014 and is based in Guilford, Connecticut.
Receive News & Ratings for Beta Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beta Bionics and related companies with MarketBeat.com's FREE daily email newsletter.
